A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
Phase 2
Active, not recruiting
- Conditions
- Chronic Myeloid LeukemiaChronic Myeloid Leukemia in RemissionBCR-ABL Positive Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 100
- Registration Number
- NCT04578847
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
Registry of Patients With Hematologic Disease and COVID-19 in Russia
Completed
- Conditions
- Coronavirus Infection and Hematologic Diseases
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 666
- Registration Number
- NCT04422470
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
🇷🇺RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, Saint Petersburg, Russian Federation
🇷🇺Regional Clinical Hospital No1, Ekaterinburg, Russian Federation
De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)
Not Applicable
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- Procedure: Autologous HSCT
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 350
- Registration Number
- NCT03462095
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT
Phase 3
- Conditions
- Mesenchymal Stem Cell Transplantation
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 20
- Registration Number
- NCT03389919
- Locations
- 🇷🇺
BMT department, Moscow, Russian Federation
R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis
Phase 3
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Drug: R-mNHL-BFM-90Drug: R-DA-EPOCH-21Drug: R-DA-EPOCH-21 + auto-SCTDrug: R-mNHL-BFM-90 + auto-SCT
- First Posted Date
- 2016-07-25
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 300
- Registration Number
- NCT02842931
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma
Phase 3
- Conditions
- Follicular Lymphoma
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 200
- Registration Number
- NCT02423837
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis
Phase 2
- Conditions
- LeukemiaMultiple Myeloma
- Interventions
- Biological: Mesenchymal stromal cells
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2014-10-21
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 40
- Registration Number
- NCT02270307
- Locations
- 🇷🇺
BMT department, Moscow, Russian Federation
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
Phase 2
- Conditions
- Graft-versus-host DiseaseRelapse
- Interventions
- Biological: Mesenchymal stem cells
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 70
- Registration Number
- NCT01941394
- Locations
- 🇷🇺
BMT department, Moscow, Russian Federation
Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia
Phase 1
- Conditions
- Septic ShockNonchemotherapy Drug-induced NeutropeniaNeutropenia After Chemotherapy in Oncohematological PatientsNeutropenia in Patients With Aplastic Anemia
- Interventions
- Drug: Standard therapy of septic shockGenetic: Mesenchymal stromal cells
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2013-05-10
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 30
- Registration Number
- NCT01849237
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia
Phase 4
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: high dose ARA-CDrug: standard dose ARA-C
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- National Research Center for Hematology, Russia
- Target Recruit Count
- 245
- Registration Number
- NCT01587430
- Locations
- 🇷🇺
National Research Center for Hematology, Moscow, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath